My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
GVK Power turns volatile after Q2 results
Nov 30,2016

Meanwhile, the S&P BSE Sensex was up 207.82 points or 0.79% at 26,601.83.

On the BSE, 6.40 lakh shares were traded on the counter so far as against the average daily volumes of 18.29 lakh shares in the past one quarter. At the days low of Rs 5.74 so far during the day, the stock has lost 1.37%. At the days high of Rs 5.94 so far during the day, the stock has risen 2.06%. The stock had hit a 52-week high of Rs 9.44 on 12 January 2016. The stock had hit a record low of Rs 4.13 on 6 June 2016. The stock had underperformed the market over the past one month till 29 November 2016, declining 12.35% compared with the Sensexs 5.54% fall. The scrip had also underperformed the market in past one quarter, sliding 7.03% as against the Sensexs 5.41% fall.

The small-cap company has equity capital of Rs 157.92 crore. Face value per share is Rs 1.

GVK Power & Infrastructure (GVK Power) reported net loss of Rs 13.41 crore in Q2 September 2016, compared with net loss of Rs 8.09 crore in Q2 September 2015. Total income rose 8.41% to Rs 18.55 crore in Q2 September 2016 over Q2 September 2015.

GVK Power & Infrastructure is a leading Indian conglomerate with presence across energy, resources, airports, transportation, hospitality and life sciences sectors.

Powered by Capital Market - Live News

Yes Bank gains after launching digital banking product
Nov 30,2016

The announcement was made during market hours today, 30 November 2016.

Meanwhile, the BSE Sensex was up 172.11 points, or 0.65%, to 26,566.12.

On the BSE, 1.48 lakh shares were so far traded in the counter, compared with average daily volume of 3.24 lakh shares in the past one quarter. The stock had hit a high of Rs 1,166.10 and a low of Rs 1,145.60 so far during the day. The stock had hit a record high of Rs 1,450 on 7 September 2016. The stock had hit a 52-week low of Rs 632.25 on 20 January 2016. The stock had underperformed the market over the past one month till 29 November 2016, falling 10.04% compared with 5.54% fall in the Sensex. The scrip had also underperformed the market in past one quarter, falling 14.44% as against Sensexs 5.41% decline.

The large-cap private sector bank has equity capital of Rs 422.75 crore. Face value per share is Rs 10.

Yes Bank announced the launch of SIMsePAY, a unique innovation that allows any account holder to do money transfers, pay utility bills and other mobile banking services, without the need for smart phones or internet.

The offering is based on a frugal sim-sleeve technology in association with Taisys Technologies, who holds global patent for the same and has implemented the same successfully in other countries including Kenya and China. The solution will cater to the large section of Indian population who remain unbanked or under banked due to lack of access to smart phones and mobile internet. This represents a large inherent market need, and hence a large scope for the solution.

The bank plans to garner a base of 5 lakh SIMsePAY by 2017. The bank has launched the services with the District Co-operative Bank, Dehradun and subsequently plans to launch it across the country.

The product will be offered in a phased manner. The first phase will involve collaboration with co-operative and regional rural banks. The second phase will involve direct outreach to the target segment through Yes Banks banking correspondent network.

Yes Bank reported 31.31% rise in net profit to Rs 801.54 crore on 24.7% rise in total income to Rs 4982.23 crore in Q2 September 2016 over Q2 September 2015.

Yes Bank is one of the leading private sector banks in India.

Powered by Capital Market - Live News

Bharat Financial extends Tuesdays rally
Nov 30,2016

Meanwhile, the S&P BSE Sensex was up 126.78 points or 0.48% at 26,520.79.

On the BSE, 2.13 lakh shares were traded on the counter so far as against the average daily volumes of 2.19 lakh shares in the past one quarter. The stock had hit a high of Rs 754.60 and a low of Rs 735.45 so far during the day. The stock had hit a 52-week high of Rs 938.75 on 29 July 2016. The stock had hit a 52-week low of Rs 434.85 on 9 December 2015. The stock had underperformed the market over the past one month till 29 November 2016, declining 16.88% compared with the Sensexs 5.54% fall. The scrip had also underperformed the market in past one quarter, sliding 7.31% as against the Sensexs 5.41% fall.

The large-cap company has equity capital of Rs 137.91 crore. Face value per share is Rs 10.

A foreign brokerage has recently maintained overweight rating on Bharat Financial Inclusion (BFIL) stock for a target price of Rs 1,125, citing the companys strong collection progress. The brokerage reportedly said that BFIL has collected 89% of its overall dues over the period from 11 November to 25 November 2016. In the wake of brokerage reports, BFIL stock had surged 7.86% to settle at Rs 734 yesterday, 29 November 2016.

Meanwhile, the company in its presentation issued to the stock exchanges before market hours yesterday, 29 November 2016, said, it is recording a collection efficiency of 97% with a 2-week lag in the wake of the governments recent demonetisation move. The company said that most of its customers cater to non-discretionary spending.

Bharat Financial Inclusions net profit rose 87.4% to Rs 145.88 crore on 38.6% increase in total income to Rs 449.60 crore in Q2 September 2016 over Q2 September 2015.

Bharat Financial Inclusion is among the largest microfinance companies in India.

Powered by Capital Market - Live News

Welspun Corp leads gainers in A group
Nov 30,2016

Welspun Corp jumped 16.29% to Rs 82.80 at 13:12 IST. The stock topped the gainers in the BSEs A group. On the BSE, 22.64 lakh shares were traded on the counter so far as against the average daily volumes of 1.22 lakh shares in the past two weeks.

Jubilant Life Sciences galloped 7.66% at Rs 709.55. The stock was second biggest gainer in A group. On the BSE, 2.54 lakh shares were traded on the counter so far as against the average daily volumes of 81,000 shares in the past two weeks.

Balkrishna Industries spurted 7.93% to Rs 994.40. The stock was third biggest gainer in A group. On the BSE, 26,000 shares were traded on the counter so far as against the average daily volumes of 4,190 shares in the past two weeks.

JK Lakshmi Cement gained 5.32% at Rs 395.80. The stock was fourth biggest gainer in A group. On the BSE, 6,114 shares were traded on the counter so far as against the average daily volumes of 25,000 shares in the past two weeks.

Crompton Greaves rose 4.54% to Rs 77.20. The stock was fifth biggest gainer in A group. On the BSE, 2.27 lakh shares were traded on the counter so far as against the average daily volumes of 3.07 lakh shares in the past two weeks.

Powered by Capital Market - Live News

Max Ventures jumps in the wake of shareholding rejig
Nov 30,2016

Meanwhile, the S&P BSE Sensex was up 81.45 points or 0.31% at 26,475.46.

On the BSE, 96,000 shares were traded on the counter so far as against the average daily volumes of 94,006 shares in the past one quarter. The stock had hit a high of Rs 54 and a low of Rs 51.85 so far during the day. The stock had hit a record high of Rs 85.80 on 7 July 2016. The stock had hit a record low of Rs 43.30 on 21 November 2016. The stock had underperformed the market over the past one month till 29 November 2016, declining 7.06% compared with the Sensexs 5.54% fall. The scrip had also underperformed the market in past one quarter, sliding 11.03% as against the Sensexs 5.41% fall.

The small-cap company has equity capital of Rs 53.40 crore. Face value per share is Rs 10.

Xenox sold 17.78 lakh shares of Max Ventures and Industries (MVIL) to Siva Enterprises at Rs 50.50 per share in a block deal on the NSE on 29 November 2016. Xenox held 5.27% stake in MVIL end September 2016. Meanwhile, Ambika Anil Raika bought 2.70 lakh shares of the company at Rs 51.03 per share in a bulk deal on the NSE on 28 November 2016.

Max Ventures and Industries consolidated net profit fell 77.5% to Rs 0.45 crore on 10.85% growth in net sales to Rs 169.89 crore in Q2 September 2016 over Q1 June 2016.

Max Ventures and Industries, through its subsidiaries, manufactures and sells biaxial oriented polypropylene films.

Powered by Capital Market - Live News

Volumes jump at Raunaq EPC International counter
Nov 30,2016

Raunaq EPC International clocked volume of 4.02 lakh shares by 12:15 IST on BSE, a 191.42-times surge over two-week average daily volume of 2,000 shares. The stock jumped 10.46% to Rs 142.

Welspun Corp notched up volume of 21.7 lakh shares, a 17.81-fold surge over two-week average daily volume of 1.22 lakh shares. The stock surged 17.7% to Rs 83.80.

IDFC Bank saw volume of 38.28 lakh shares, a 6.63-fold surge over two-week average daily volume of 5.78 lakh shares. The stock dropped 3.94% to Rs 68.25.

Jai Corp clocked volume of 9.44 lakh shares, a 5.75-fold surge over two-week average daily volume of 1.64 lakh shares. The stock surged 9.45% to Rs 70.65.

Vivimed Labs saw volume of 5.18 lakh shares, a 4.8-fold rise over two-week average daily volume of 1.08 lakh shares. The stock jumped 8.5% to Rs 100.20 after the company said its FDF manufacturing facility in Alathur, near Chennai has a favourable outcome post its United States Food and Drug Administration inspection. The announcement was made after market hours yesterday, 29 November 2016. The audit was conducted during the last week of November and concluded on 28 November 2016.

Furthermore, Vivimed obtained abbreviated new drug application (ANDA) approval for Metronidazole and same is commercialised. During November 2016, the company acquired ANDA of Zolpidem and the file transfer has successfully been completed. It is expected to be commercialised by Q4 March 2017.

Powered by Capital Market - Live News

UCO Bank gains after allotting preferential shares to LIC
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the S&P BSE Sensex was up 104.27 points or 0.4% at 26,498.28.

On the BSE, 63,000 shares were traded on the counter so far as against the average daily volumes of 2.22 lakh shares in the past one quarter. The stock had hit a high of Rs 34.30 and a low of Rs 33.85 so far during the day. The stock had hit a 52-week high of Rs 50.15 on 1 December 2015. The stock had hit a 52-week low of Rs 27.80 on 15 February 2016. The stock had outperformed the market over the past one month till 29 November 2016, declining 3.31% compared with the Sensexs 5.54% fall. The scrip had, however, underperformed the market in past one quarter, sliding 16.52% as against the Sensexs 5.41% fall.

The mid-cap bank has equity capital of Rs 1488.03 crore. Face value per share is Rs 10.

The shares issued to Life Insurance Corporation of India (LIC) will be under lock-in for a period of one year from the date of trading from the stock exchanges. LIC owned 11.88% stake in UCO Bank end September 2016.

UCO Bank reported net loss of Rs 384.83 crore in Q2 September 2016, compared with net profit of Rs 156.20 crore in Q2 September 2015.

The Government of India held 77.54% stake in UCO Bank end September 2016.

Powered by Capital Market - Live News

Eros International advances on fund raising plans
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the BSE Sensex was up 115.17 points, or 0.44%, to 26,509.66.

On the BSE, 7,267 shares were traded so far in the counter, compared with average daily volume of 43,372 shares in the past one quarter. The stock had hit a high of Rs 174.90 and a low of Rs 170.10 so far during the day. The stock had hit a 52-week high of Rs 274 on 4 December 2015. The stock had hit a 52-week low of Rs 125.90 on 29 February 2016. The stock had underperformed the market over the past one month till 29 November 2016, falling 12.25% compared with 5.54% fall in the Sensex. The scrip had also underperformed the market in past one quarter, falling 21.39% as against Sensexs 5.41% decline.

The small-cap company has equity capital of Rs 93.71 crore. Face value per share is Rs 10.

Eros International Media said that the meeting of board of directors of the company will be held on 2 December 2016, to consider and approve the proposal to raise funds through issue and offer of secured/unsecured, redeemable, non convertible debentures on public/private placement basis, in one or more tranches, upto the limit as may be decided by the board.

On a consolidated basis, net profit of Eros International Media fell 32.9% to Rs 62.99 crore on 5.2% decline in net sales to Rs 478.79 crore in Q2 September 2016 over Q2 September 2015.

Eros International Media operates in the Indian film entertainment industry. It acquires, co-produces and distributes Indian films across all available formats such as cinema, television and digital new media.

Powered by Capital Market - Live News

HCC nudges higher on mulling preferential share allotment
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the S&P BSE Sensex was up 131.10 points or 0.5% at 26,525.11.

On the BSE, 3.95 lakh shares were traded on the counter so far as against the average daily volumes of 28.59 lakh shares in the past one quarter. The stock had hit a high of Rs 34.70 and a low of Rs 34.25 so far during the day. The stock had hit a 52-week high of Rs 41.90 on 14 September 2016. The stock had hit a 52-week low of Rs 16.60 on 12 February 2016. The stock had underperformed the market over the past one month till 29 November 2016, declining 7.02% compared with the Sensexs 5.54% fall. The scrip had, however, outperformed the market in past one quarter, surging 46.96% as against the Sensexs 5.41% fall.

The small-cap company has equity capital of Rs 77.92 crore. Face value per share is Rs 1.

Hindustan Construction Companys (HCC) board at its proposed board meeting on 2 December 2016, would consider issue of equity shares representing 24.44% of the expanded capital and also optionally convertible debentures (OCDs) on preferential basis, to be allotted collectively to the individual lenders. In this context, the company plans to convene an extraordinary general meeting (EGM) for seeking shareholders approval.

HCCs net profit fell 42.8% to Rs 23.08 crore on 8.2% decline in net sales to Rs 759.03 crore in Q2 September 2016 over Q2 September 2015.

HCC is into infrastructure development in transportation, power and water segments.

Powered by Capital Market - Live News

Sarda Energy & Minerals spurts after restarting mining operations
Nov 30,2016

The announcement was made after trading hours yesterday, 30 November 2016.

Meanwhile, the BSE Sensex was up 92.11 points, or 0.35%, to 26,486.12.

On BSE, so far 59,000 shares were traded in the counter, compared with average daily volume of 86,198 shares in the past one quarter. The stock hit a high of Rs 256.65 and a low of Rs 235.50 so far during the day. The stock hit a 52-week high of Rs 296.60 on 1 November 2016. The stock hit a 52-week low of Rs 75.50 on 26 February 2016. The stock had underperformed the market over the past 30 days till 29 November 2016, falling 15.83% compared with the 5.50% decline in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 33.55% as against Sensexs 7.23% decline.

The small-cap company has equity capital of Rs 36.02 crore. Face value per share is Rs 10.

On 9 March 2016, Sarda Energy & Minerals announced temporary suspension of operation at its iron ore mine in Dongarbore (Chhattisgarh) after a naxalite attack on 7 March 2016, which caused death of one employee and damage of a few vehicles.

Net profit of Sarda Energy & Minerals rose 250.3% to Rs 12.54 crore on 2.7% decline in net sales to Rs 253 crore in Q2 September 2016 over Q2 September 2015.

Sarda Energy & Minerals (SEML) is one of the lowest cost producers of steel (sponge iron, billets, ingots, TMT bars) and one of the largest manufacturers and exporters of ferro alloys in India.

Powered by Capital Market - Live News

Vivimed Labs spurts after unit successfully completes USFDA inspection
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the S&P BSE Sensex was up 78.36 points or 0.3% at 26,472.37.

On the BSE, 3.78 lakh shares were traded on the counter so far as against the average daily volumes of 2.89 lakh shares in the past one quarter. The stock had hit a high of Rs 107.40 and a low of Rs 102 so far during the day. The stock had hit a record high of Rs 121.15 on 4 October 2016. The stock had hit a 52-week low of Rs 68 on 9 August 2016. The stock had underperformed the market over the past one month till 29 November 2016, declining 13.97% compared with the Sensexs 5.54% fall. The scrip had, however, outperformed the market in past one quarter, advancing 24.63% as against the Sensexs 5.41% fall.

The large-cap company has equity capital of Rs 16.20 crore. Face value per share is Rs 2.

The audit was conducted during the last week of November and concluded on 28 November 2016. Furthermore, Vivimed obtained abbreviated new drug application (ANDA) approval for Metronidazole and same is commercialised. During November 2016, the company acquired ANDA of Zolpidem and the file transfer has successfully been completed. It is expected to be commercialised by Q4 March 2017.

Vivimed is on track of its filing targets and has successfully completed 3 ANDA filings during the current financial year and expect one more filing to be completed by Q4 March 2017. These products provide vertical integration with the in-house active pharmaceutical ingredients (APIs).

Santosh Varalwar, Managing Director of Vivimed Labs, said the company is on track with its filings pipeline which are expected to bear fruits when these products start to commercialise over the next 18-24 months.

On a consolidated basis, Vivimed Labs net profit rose 12.4% to Rs 26.85 crore on 11.5% decline in net sales to Rs 298.36 crore in Q2 September 2016 over Q2 September 2015.

Vivimed Labs is a niche specialty chemicals and pharmaceuticals company.

Powered by Capital Market - Live News

Lupin gains after receiving USFDA approval for Armodafinil tablets
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the BSE Sensex was up 67.23 points, or 0.25%, to 26,461.24.

On BSE, so far 25,000 shares were traded in the counter, compared with average daily volume of 99,927 shares in the past one quarter. The stock hit a high of Rs 1,545.55 and a low of Rs 1,526.90 so far during the day. The stock hit a 52-week high of Rs 1,911.55 on 9 February 2016. The stock hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had outperformed the market over the past 30 days till 29 November 2016, falling 0.06% compared with the 5.50% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 2.25% as against Sensexs 7.23% decline.

The large-cap company has equity capital of Rs 90.27 crore. Face value per share is Rs 2.

Lupin announced that its US subsidiary Lupin Pharmaceuticals Inc (LPI) has received final approval from the United States Food and Drug Administration (USFDA) to market Armodafinil tablets 50mg, 150mg, 200mg and 250mg. LPI shall commence promoting the product in the US shortly. Lupins Armodafinil tablets are the AB rated generic equivalents of Cephalon, Incs Nuvigil tablets. Armodafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy or shift work disorder (SWD). Nuvigil tablets had annual US sales of $515.6 million as per IMS MAT September 2016 data.

Lupins consolidated net profit jumped 57.8% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, central nervous system (CNS), GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Powered by Capital Market - Live News

Tata Power witnesses initial volatility post impressive Q2 numbers
Nov 30,2016

Meanwhile, the S&P BSE Sensex was up 70.19 points or 0.27% at 26,464.20.

On the BSE, 1.34 lakh shares were traded on the counter so far as against average daily volume of 4.82 lakh shares in the past one quarter. The stock had hit a high of Rs 72.75 and a low of Rs 71.05 so far during the day. The stock had hit a 52-week high of Rs 84.45 on 24 October 2016. The stock had hit a 52-week low of Rs 55 on 12 February 2016. The stock had underperformed the market over the past one month till 29 November 2016, declining 7.97% compared with the Sensexs 5.54% fall. The scrip had, however, outperformed the market in past one quarter, sliding 4.87% as against the Sensexs 5.41% fall.

The large-cap company has equity capital of Rs 270.46 crore. Face value per share is Rs 270.46.

Tata Power Company (Tata Power) reported consolidated net profit of Rs 336 crore in Q2 September 2016, compared with net loss of Rs 96 crore in Q2 September 2015. Consolidated total income from operations declined 5.96% to Rs 7209 crore in Q2 September 2016 over Q2 September 2015, due to lower revenue at standalone level due to lower fuel cost & lower power purchase, lower million units (MUs) traded at Tata Power Trading Company (TPTCL).

The company reported a turnaround in bottom line in Q2 September 2016 vis-n++-vis corresponding previous quarter mainly due to lower mark-to-market (MTM) losses at Coastal Gujarat Power (CGPL) and better performance by key Indian subsidiaries and Indonesian coal mines.

Tata Powers CEO & Managing Director Anil Sardana said, the company has improved profitability and has maintained strong operational performance across all business verticals. The companys subsidiaries continue to perform well despite challenging circumstances. Management is confident that the companys strong growth trajectory will continue into the next quarter, Sardana said.

Tata Powers 100% subsidiaries viz. Bhira Investments nd Bhivpuri Investments (selling companies) had signed an agreement for sale and purchase of shares on 30 January 2014, to sell its 30% stake in PT Arutmin, Indonesia and associated trading and infrastructure companies for an aggregate consideration of $510 million. Consequent to certain closing adjustments to the sale consideration and other changes agreed between the parties, the selling companies have signed revised definitive agreements with PT Cakrawala Langit Sejahtera (PT CLS) a Bakrie group entity on 28 November 2016.

The sale consideration for PT Arutmin is now revised to $246.64 million from the earlier value of $390 million, pursuant to closing adjustments relating to certain prior period liabilities, which includes settlement of past claims with mining contractor, pursuant to a court order (about $80 million as companys share) and other statutory liabilities (about $50 million.). The consideration is expected to be received in a phased manner over next few years.

With regard to the infrastructure company PT Mitratama Perkasa (PTMP), in which PT Sumber Energi Andalan Tbk (Sumber) holds Tata Powers 30% equity; and Trust Energy Resources Pte, a 100% subsidiary of the company (Trust Energy) which holds Sumber, has entered into an agreement with Rwood Resources, a Bakrie Group Entity, for divestment of 94.61% stake in Sumber. The sale consideration for Infrastructure companies is now revised to $154.28 million from the earlier value of $120 million, pursuant to closing adjustments relating to prior period. The consideration is expected to be received in a phased manner over next few years.

Meanwhile, Tata Powers board decided to convene an extraordinary general meeting of the shareholders of the company on 26 December 2016, for considering and passing a resolution for removal of Cyrus P. Mistry as director of the company.

Tata Power is Indias largest integrated power company with a growing international presence. The company together with its subsidiaries and jointly controlled entities has an installed gross generation capacity of 10,477 megawatts (MW) and a presence in all the segments of the power sector viz. fuel security and logistics, generation, transmission, distribution and trading.

Powered by Capital Market - Live News

JHS Svendgaard declines as Tano Mauritius liquidates bulk shares
Nov 29,2016

Meanwhile, the S&P BSE Sensex was up 39.12 points or 0.15% at 26,389.29.

On the BSE, 98,000 shares were traded on the counter so far as against average daily volumes of 78,744 shares in the past one quarter. The stock had hit a high of Rs 41.30 and a low of Rs 37 so far during the day. The stock had hit a 52-week low of Rs 12.71 on 20 December 2015. The stock had hit a 52-week high of Rs 46.30 on 1 November 2016. The stock had outperformed the market over the past one month till 28 November 2016, declining 4.24% compared with the Sensexs 5.7% fall. The scrip had also outperformed the market in past one quarter, advancing 12.06% as against the Sensexs 5.15% fall.

The small-cap company has equity capital of Rs 39.87 crore. Face value per share is Rs 10.

Tano Mauritius India FVCI owned 6.65% stake in JHS Svendgaard Laboratories end September 2016.

On a consolidated basis, JHS Svendgaard Laboratories reported net profit of Rs 1.35 crore in Q2 September 2016, compared with net loss of Rs 0.92 crore in Q2 September 2015. Net sales rose 20.7% to Rs 30.65 crore in Q2 September 2016 over Q2 September 2015.

JHS Svendgaard Laboratories is engaged in exporting, importing, trading, buying and selling of oral care/hygiene products (including toothbrushes and toothpastes).

Powered by Capital Market - Live News

Cadila Healthcare corrects on profit booking
Nov 29,2016

Meanwhile, the BSE Sensex was up 132.61 points, or 0.50%, to 26,482.78.

On BSE, so far 24,000 shares were traded in the counter, compared with average daily volume of 70,800 shares in the past one quarter. The stock hit a high of Rs 414.60 and a low of Rs 399.10 so far during the day. The stock hit a 52-week high of Rs 429.45 on 1 November 2016. The stock hit a 52-week low of Rs 295.50 on 18 January 2016. The stock had outperformed the market over the past 30 days till 28 November 2016, falling 1.86% compared with the 5.66% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 6.50% as against Sensexs 7.03% decline.

The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.

Shares of Cadila Healthcare rose 12.51% in five trading sessions to settle at Rs 411 yesterday, 28 November 2016, from its close of Rs 365.30 on 21 November 2016.

Cadila Healthcares consolidated net profit fell 28.93% to Rs 337.60 crore on 3.08% increase in net sales to Rs 2336.30 crore in Q2 September 2016 over Q2 September 2015.

Cadila Healthcare is a global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News